Plain-English translation of NCT07314294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called EMB-01 in people whose colorectal cancer has spread to other parts of the body or has returned after earlier treatments. Researchers want to find the best way to give this medication—either as a weekly injection throughout the study, or weekly for the first 6 weeks and then every two weeks after that. The goal is to see how well the medication works and how safe it is for this group of patients.
Colorectal cancer that has spread or come back is very difficult to treat, and patients often run out of treatment options after standard therapies stop working. This trial exists to see whether this new medication can help people whose cancer no longer responds to older treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive the medication either once a week for the entire study, or once a week for 6 weeks followed by once every two weeks. You will visit the clinic regularly for the medication injections and blood work. Every 6 weeks for the first 12 visits, and then less frequently after that, you will have CT or MRI scans to see how your cancer is responding. The study will assess how well the medication is working and watch carefully for any side effects.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China